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of aging (Beckman and Ames, 1998; Vina et al., 2003; Harman, 
2006). Mitochondria were brought to attention in aging biology 
due to the central role of mitochondria in producing biochemical 
energy (ATP) to meet cellular requirements in aerobic cells and to 
the decline of basal metabolic rate and of physical performance that 
are characteristic of aging. Moreover, mitochondria are considered 
likely pacemakers of tissue aging due to their continuous produc-
tion of the free radicals superoxide (O2
-) and nitric oxide (NO), to 
the mitochondrial sensitivity to free radical mediated oxidative 
damage and to the accumulation of phospholipid, protein, and 
DNA oxidation products in aged animals (Beckman and Ames, 
1998; Vina et al., 2003; Harman, 2006).
In mammalian brain aging, more precisely in rats and mice, 
the accumulation of dysfunctional brain mitochondria with 
decreased rates of electron transfer in complexes I and IV and of 
ATP production is associated with the accumulation of oxidation 
products of phospholipids and proteins, and these characteristics 
appear as determining factors in brain aging. The evidence sup-
porting this concept is the inverse relationships between accu-
mulated oxidative damage (protein carbonyls and TBARS) and 
the rates of electron transfer and enzymatic activity (Figure 1A), 
the direct relationships between the rates of electron transfer in 
complexes I and IV and the enzymatic activity of mtNOS with 
MaMMalian aging and brain Mitochondrial 
iMpairMent in aging and neurodegenerative 
diseases
Mammalian aging is characterized by a gradual and continuous 
loss, starting at full adulthood, of the quality of all physiological 
functions and responses involving all organs and tissues. However, 
the losses are more marked in the functions that depend on inte-
grated responses of the central nervous system (Gilad and Gilad, 
1995). The whole economy of the body is involved in the aging 
process and a decreased basal metabolic rate is recognized as one of 
the traits of old mammals. In the study of mammalian aging there is 
a continuous interplay between the concept of loosing physiological 
functions, adequately expressed by the fraction at a given age of the 
function at full adulthood, and the concept of survival or extension 
of life, that is expressed by the median or maximal life span.
The free radical theory of aging is based on the works of 
Gerschaman et al. (1954) and Harman (1956) that considered 
that aging is caused by the continuous inactivation of biologically 
essential macromolecules due to chemical modifications produced 
in reactions mediated by oxygen free radicals. When the free radi-
cal theory of aging, that lacked the precision of the subcellular 
location of the oxidative reactions mediated by free radicals, is 
focused in mitochondria, it emerges as the mitochondrial theory 
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neurological performances ( neuromuscular coordination and 
 exploratory  activity) (Figure 1B) and the direct relationships 
between enzymatic activity of complexes I and IV and of mtNOS 
with the median and maximal life span in the same mice (Figure 
1C) (Boveris and Navarro, 2008a). Accordingly, aged mamma-
lian brain has a decreased capacity to produce ATP by oxidative 
phosphorylation and it is considered that this decreased capac-
ity for energy production becomes limiting under physiological 
conditions in aged individuals. For instance, brain mitochondria 
isolated from mice at the time point of 50% survival (median life 
span) show about 50% of the activity at full adulthood of criti-
cal enzymes, such as complex I (NADH-ubiquinone reductase), 
complex IV (cytochrome oxidase) and mitochondrial nitric oxide 
synthase (mtNOS) (Navarro and Boveris, 2007a,b).
The current knowledge indicates that the impairment of brain 
mitochondrial function in aging is mainly due to decreased elec-
tron transfer rates in complexes I and IV, among other decreased 
mitochondrial activities. There was a hypothesis in the field that 
accumulation of phospholipid hydroperoxides and other oxidation 
products in aging would lead to structural modifications of the 
bilayer with an increased permeability of the inner membrane to 
H+ and water. There are no reports on the effect of aging either 
on H+ permeability, the key property of the inner membrane in 
the chemiosmotic mechanism of oxidative phosphorylation, or 
on brain uncoupling proteins (Mattiasson and Sullivan, 2006). 
Increased water permeability was reported in brain mitochon-
dria in aged rats (Navarro and Boveris, 2004). Concerning the 
effect of aging on brain ATP-synthase activity, it has been reported 
that brain aging is associated with a markedly decreased ATP-
synthase activity with nitration of the Tyr269 of the β-subunit (Lam 
et al., 2009).
Mitochondrial dysfunction in terms of decreased rates of elec-
tron transfer in complex I and IV and decreased mitochondrial 
respiration with NAD-dependent substrates has been consistently 
observed in brain mitochondria isolated from aged rats and mice 
(Vitorica et al., 1985; Beckman and Ames, 1998; Navarro and 
Boveris, 2004, 2007b; Navarro et al., 2004, 2005a, 2007; Cocco et al., 
2005). Interestingly, the phenomenon is more marked in specific 
rat brain areas that are understood as more affected by the aging 
process, such as hippocampus and cerebral cortex (Navarro et al., 
2008).
Mitochondria isolated from the brain of aged rats and mice show 
increased contents of the oxidation products of phospholipids, pro-
teins, and DNA, decreased membrane potential, and increased size 
and fragility (Beckman and Ames, 1998; Navarro and Boveris, 2004, 
2007b). The oxidative damage is also more marked in hippocampus 
and cerebral cortex than in whole brain (Navarro et al., 2008).
Human neurodegenerative diseases are characterized by 
cumulative neuronal damage in specific brain areas that leads to 
neurological deficits when neuronal loss reaches a critical limit. 
For instance, Parkinson’s disease evolves for years before typical 
motor signs appear with a loss of about 60% of the dopamin-
ergic neurons of substantia nigra pars compacta. There is grow-
ing evidence that mitochondrial dysfunction and impairment of 
the respiratory complexes is associated with the neuronal loss in 
neurodegenerative diseases. Decreased complex IV activity has 
been reported in Alzheimer’s disease (Chagnon et al., 1995) and 
Figure 1 | Statistical correlations involving: (A) mitochondrial enzyme 
activities (complexes i and iV and mtNOS) and mitochondrial oxidative 
damage (r2 = 0.84; p < 0.01 for complexes i and iV; r2 = 0.90; p < 0.01 for 
mtNOS); (B) enzyme activities and neurological tests (tightrope, 
r2 = 0.62; p < 0.001; T-maze, r2 = 0.56; p < 0.05) and enzyme activities and 
median (r2 = 0.46; p < 0.05), and maximal (r2 = 0.31; p < 0.01), life spans (C) 
in male mice. Data from (Navarro et al., 2002, 2004, 2005a, 2007). For the 
neurological assays, individual mice were subjected every 2 weeks to the 
tightrope and the T-maze tests (Navarro et al., 2002). For the tightrope test, 
mice were placed hanging from their anterior legs in the middle of a 60-cm 
tightrope and the test was considered successful when mice reached the 
column at the end of the rope in less of 30 s. For the T-maze test, mice were 
challenged in a T-shaped maze of 50 cm arms and the test was considered 
successful when mice moved toward the T-intersection in less than 30 s. 
Modified from Boveris and Navarro (2008a,b).
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 complex I; low concentrations of detergents, natural and synthetic 
steroids (Boveris and Stoppani, 1971) and hydrophobic pesticides 
[rotenone and pyridaben (Gomez et al., 2007)] are effective in dis-
rupting intra-complex I polypeptide hydrophobic bonds and in 
inhibiting complex I electron transfer activity. The rate of electron 
transfer in complex I is relatively high; NADH oxidation proceeds 
at 250–500 nmol/min mg protein, as compared with the rate of 
electron transfer of complex II (UQH
2
-cytochrome c reductase) 
of 100–150 nmol/min mg protein (Brown and Borutaite, 2004). 
Complex I by auto-oxidation with molecular O
2
 produces signifi-
cant amounts of O2
-
 by the collisional reaction of O
2
 with the flavin 
semiquinone FMNH. (Chance et al., 1979; Boveris and Cadenas, 
2000; Turrens, 2003). The rate of O2
-  production by complex I is 
increased by electron transfer inhibition with rotenone (Boveris 
and Chance, 1973) and by complex I dysfunction in choline defi-
ciency (Hensley et al., 2000).
It is currently accepted that mitochondrial complex I is par-
ticularly sensitive, in terms of inactivation, to oxidants, oxygen free 
radicals, and reactive nitrogen species. This special characteristic is 
frequently referred as the “complex I syndrome”, with the symptoms 
of reduced mitochondrial respiration in state 3 (with ADP) and 
with malate–glutamate as substrate and of reduced complex I activ-
ity. This “complex I syndrome” has been observed in Parkinson’s 
disease and in other neurodegenerative diseases (Schapira et al., 
1990a,b; Carreras et al., 2004; Schapira, 2008; Navarro et al., 2009), 
as well as in aging (Boveris and Navarro, 2008a) and in ischemia-
reperfusion (Gonzalez-Flecha et al., 1993). The molecular mecha-
nism involved in the inactivation of complex I is likely accounted 
by the sum of ONOO− mediated reactions, reactions with the 
free radicals intermediates of the lipid peroxidation process (R. 
and ROO.) and amine–aldehyde adduction reactions. It is now 
understood that the three process above mentioned alter the native 
non-covalent polypeptide interactions of complex I and promote 
synergistically protein damage and inactivation by shifting the non-
covalent bonding to covalent cross linking (Liu et al., 2003).
nitric oxide and peroxynitrite as coMplex i 
inhibitors
Both, NO and ONOO− have been reported as direct inhibitors of 
complex I. It has been claimed that NO inhibits mitochondrial 
complex I activity by S-nitrosylation and Fe-nitrosation (Brown 
and Borutaite, 2004). On the other hand, irreversible inhibition of 
brain mitochondrial complex I by ONOO− was reported (Riobo 
et al., 2001). The current ideas are that the chronic toxic effects of 
NO in the brain are explained by the cumulative nitrations of com-
plex I proteins due to ONOO− increased levels in the mitochondrial 
matrix where it is produced in the termination reaction of the two 
free radicals O2
-  and NO. It is considered that the anion ONOO− is 
confined to the mitochondrial matrix, since it is charged and there 
is no recognized transporter. Superoxide radical is produced physi-
ologically in mitochondria by the autoxidation reactions of FMN. 
and UQH. at a rate of 0.80–0.90 nmol O2
- /min mg protein resulting 
in a steady state concentration of 0.1–0.2 nM in the mitochondrial 
matrix (Boveris and Cadenas, 2000; Boveris et al., 2006; Valdez et al., 
2006). In the same physiologic conditions and by the enzymatic 
reaction of mitochondrial nitric oxide synthase (mtNOS), NO is 
produced at a rate of 1.0–1.4 nmol NO/min mg protein and kept 
decreased complex I activity is usually reported in the substantia 
nigra of  postmorten samples in Parkinson’s disease (Mizuno et al., 
1989; Mann et al., 1992).
Mitochondria and parkinson’s disease
There is considerable evidence for a mitochondrial involvement 
in sporadic Parkinson’s disease. Experimental data indicate that 
Parkinson’s disease is associated to two interdependent conditions 
of brain mitochondria: mitochondrial dysfunction and mitochon-
drial oxidative damage. Several studies have shown mitochondrial 
dysfunction and reduced activity of mitochondrial complex I in 
substantia nigra (Schapira et al., 1990a,b; Schapira, 2008) and in 
frontal cortex (Navarro et al., 2009) in Parkinson’s disease patients. 
Moreover, similar mitochondrial complex I dysfunctions were 
reported in skeletal muscle and platelets of Parkinson’s disease 
patients (Mann et al., 1992). This condition of complex I impair-
ment is likely to be of pathogenic importance because intoxication 
of experimental animals with inhibitors of complex I (rotenone, 
pyridaben, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) 
and its metabolite 1-methyl-4-phenylpyridinium (MPP+) (Bougria 
et al., 1995; Gomez et al., 2007) reproduce the clinical symptoms of 
Parkinson’s disease in humans. Moreover, multiple genes in which 
mutations or polymorphisms increase the risk of Parkinson’s dis-
ease are linked to mitochondrial functions. Inhibition of complex 
I creates a biochemical environment with increased reduction of 
the FMN and high levels of the FMNH. semiquinone that increase 
the generation of O2
- . In turn, the increased rate of O2
-  generation 
promotes lipid peroxidation, protein oxidative damage and perox-
ynitrite (ONOO−) mediated protein nitration (as 3-nitrotyrosine) 
and nitrosylation (as –S–NO of thiol groups), in a process that lead 
neurons to apoptosis (Navarro and Boveris, 2009) and to aggre-
gation of α-synuclein with the subsequent death of dopaminer-
gic neurons (Dawson and Dawson, 2003). There are numerous 
reports linking α-synuclein, mitochondrial dysfunction, and oxida-
tive stress; however, reports are neither consistent in the causality 
nor in the cross-effects of oxidative stress and α-synuclein expres-
sion and polymerization. It is a current hypothesis in the field that 
cytosolic oxidative stress (increased GSSG and H
2
O
2
 levels) favor 
the post-translational oxidative modification of α-synuclein and 
its aggregation.
Mitochondrial coMplex i, the “coMplex i syndroMe” 
and parkinson’s disease
Mitochondrial complex I (NADH-UQ reductase) catalyzes electron 
transfer from NADH to ubiquinone and is the molecular path-
way to connect the tricarboxylic acid cycle and NADH with the 
mitochondrial respiratory chain. Complex I is a supra-molecular 
protein complex of 850 kDa composed of about 40 polypeptide 
units and contains FMN and iron–sulfur clusters as redox active 
centers. Seven polypeptides of complex I are encoded by mitochon-
drial genes (ND 1, 2, 3, 4, 4L, 5, and 6). Complex I components 
include a 54-kDa flavoprotein, 24, 75, and 49 kDa proteins, and 
the proteins TYKY and PSST that are bound to the inner mem-
brane and that transfer electrons to UQ (Walker, 1992). Two com-
plex I-linked UQ-pools have been detected (Raha and Robinson, 
2000). Non-covalent hydrophobic bonds and van der Waals’ weak 
bonds are important in keeping together the whole structure of 
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(Gatto et al., 2000). The role of increased levels of NO in Parkinson’s 
disease gained significance by the finding of 3-nitrotyrosine in the 
core of Lewy bodies, the pathological hallmark of the disease (Good 
et al., 1998). The presence of 3-nitrotyrosine, the ‘‘footprint’’ of 
ONOO− high levels, was observed in brain mitochondria of rats 
treated with MTPT and its metabolite MPP+ and prevented by 
previous administration of 7-nitroindazole, a relatively specific 
nNOS inhibitor. Moreover, nNOS-gene deficient mice are more 
resistant to the toxic effects of MPTP than wild-type animals. In 
agreement, in SH-SY5Y neuroblastoma cells, MPTP and MPP+ 
increase the mitochondrial production of NO, suggesting an acti-
vating effect on mtNOS that is associated to Bax increase, release of 
cytochrome c and caspase activation (Dennis and Bennett, 2003). 
It was also reported that oxidative stress induced by complex I 
inhibition biphasically activated the pro-apoptotic factor c-Jun-
N-terminal kinase (JNK) and the transcription factor NF-κB 
(Cassarino et al., 2000).
The action of the mentioned inhibitors (ONOO−, ROOH, ROO., 
intermediates and aldehydes from the lipid peroxidation processes), 
on complex I leads to denaturation of the protein structure and fur-
ther increases of O2
-  and ONOO− production at the vicinity of com-
plex I itself, tending to the perpetuity of this metabolic abnormality 
which is relevant for the chronic situations of neurodegeneration.
coMplex i syndroMe in patients with parkinson’s 
disease and with deMentia with lewy bodies
Recently, moderate and marked impairments of tissue respiration, 
state 3 mitochondrial respiration with malate–glutamate as sub-
strate and complex I decreased activity, associated with oxidative 
damage were determined in frozen samples of frontal cortex (area 
8) of patients with Parkinson’s disease and with dementia with Lewy 
bodies in comparison to age-matched healthy controls (Table 1) 
(Navarro et al., 2009). The observed mitochondrial impairment is 
properly described as a reduced tissue respiration of frontal cor-
tex with reduced mitochondrial respiration with NAD-dependent 
substrates and with a marked decrease in complex I activity. The 
decreases in respiratory rates and in enzymatic activities were 
associated with oxidative damage, as determined by the increased 
contents of phospholipid and protein oxidation products. It is to 
note that cortex mitochondrial dysfunction is now added to the 
classical recognition of mitochondrial dysfunction in the dopamin-
ergic neurons of substantia nigra in Parkinson’s disease which was 
early considered as specific (Schapira et al., 1990a).
The markedly higher mtNOS activity observed in human fron-
tal cortex (4.0–7.0 nmol NO/min mg protein (Table 1) in com-
parison with the mtNOS activities in mouse and rat whole brain 
and frontal cortex (0.64–0.67 nmol NO/min mg protein (Navarro 
et al., 2008) set the basis for the speculation that this level of brain 
mtNOS expression corresponds to an adaptive response of the 
highly evolved human brain, as part of the human extraordinary 
capacity for homeostatic maintenance and longevity. Cutler and 
co-workers introduced the concept that Cu,Zn-SOD and Mn-SOD 
activities in various organs, evolved in mammals as determinants 
of life span (Tolmasoff et al., 1980; Cutler, 1991). Similarly, it is 
reasonable to consider that human brain acquired upon evolution 
an adaptive resistance to brain cortex mitochondrial dysfunction 
and oxidative damage.
at a steady state level of 200–350 nM in the mitochondrial matrix 
(Boveris et al., 2006; Valdez et al., 2006). Both radicals react in a 
diffusion controlled reaction (k = 1.9 × 1010 M−1 s−1) and generate 
ONOO− at a rate of 0.38 μM/s in the mitochondrial matrix or 
0.92 nmol/min mg protein (Valdez et al., 2000). Peroxynitrite is 
normally reduced by the mitochondrial reductants NADH
2
, UQH
2
 
and GSH and kept at an intramitochondrial steady state level of 
2–5 nM (Valdez et al., 2000). When this level is increased in excess, 
up to 25–40 nM, it leads to tyrosine nitration, protein oxidation, 
and damage to iron sulfur centers with sustained complex I inhibi-
tion and increased generation of O2
-  by complex I. The available 
evidence indicates that increased mitochondrial matrix NO levels, 
secondary to mtNOS over-expression or activation or to NO dif-
fusion from cytosolic NOS, leads to ONOO−-mediated nitration, 
to inhibition of complex I enzymatic activity, to increased produc-
tion of O2
-  and to the turning of normal cell signaling by H
2
O
2
 and 
NO to ONOO−-initiated apoptotic signaling. The normal signaling 
role of NO and H
2
O
2
 is supported by the developmental biology 
observation that the 144-kDa brain mtNOS increases several folds 
in the pre- and post-natal periods in rats in parallel to brain and 
cerebellum development (Riobo et al., 2002).
At this point, it is convenient to briefly address the current status 
of mtNOS, the mitochondria-located member of the NOS family. 
This enzyme activity was first described in rat liver mitochondria by 
Ghafourifar and Richter (1997) and by Giulivi et al. (1998). At the 
beginning there was a skeptical attitude toward this new enzyme but 
in a few years mtNOS activities were reported in a series of mouse 
and rat organs such as brain, heart, kidney, thymus, and skeletal 
muscle with a mean activity of about 0.90 nmol NO/min × mg 
protein (Boveris and Navarro, 2008b). The idea of contamination 
faded away because it seemed unreasonable that mitochondria of 
various tissues would show a similar contamination with cytosolic 
NOS. In 2002, Giulivi and co-workers in a transcendent contribu-
tion (Elfering et al., 2002) sequenced rat liver mtNOS and identified 
the enzyme as an inner membrane protein and as the transcript of 
nNOS, splice variant α, myristylated and phosphorylated. Decisive 
evidence was provided by Kanai et al. (2001) with the electrochemi-
cal determination of the Ca2+-induced NO release from a single 
mouse heart mitochondrion, a process that was abolished in nNOS 
−/− knock out mice. The current understanding is that mtNOS is 
the result of the specific and controlled translocation of a cytosolic 
transcript of genomic nNOS.
In this context, the transcriptional regulation of the two brain 
NOS, the cytosolic nNOS and the mitochondrial mtNOS, are 
particularly relevant. A bipolar and complementary distribution 
of NOS activities in cells has been proposed; one in mitochon-
dria (mtNOS) and the other one (nNOS or eNOS) in the cytosol 
(Navarro and Boveris, 2008). There are reports of over-expression 
of nNOS in the brain of patients with Parkinson’s disease (Eve 
et al., 1998) and of increased levels of cytosolic nNOS in aging rats 
(Lam et al., 2009). In the latter case, proteomic analysis revealed a 
selective and almost specific nitration of the ATP-synthase at Tyr269, 
explained by the higher level of ONOO− in the mitochondrial 
matrix as compared with the cytosol (Lam et al., 2009).
The observed nNOS over-expression and the presence of 3-ni-
trotyrosine in circulating neutrophils from Parkinson’s disease 
patients, suggests a generalized deregulation of the nNOS gene 
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and of mitochondrial dysfunction are simultaneous. The mito-
chondrial increase in oxidation products has been interpreted as 
the result of a continuous process of phospholipid and protein 
oxidation. It is becoming clear that mitochondria continuously 
and simultaneously respire, produce O2
-  and NO, are subjected to 
free radical mediated processes that produce lipid peroxidation 
and protein oxidation and loose enzymatic activity. The loosing of 
enzymatic activity is also called the appearance of dysfunctional 
mitochondria. It is speculated that dysfunctional mitochondria, as 
they are defined by sub-normal or partially inactivated respiration, 
enzymatic activity, and ATP-production, have an extended time for 
mitochondrial turnover, which is associated with a higher level of 
mitochondrial oxidation products. It is also speculated that this 
high level of oxidation products is enough to trigger apoptosis, 
before de novo mitochondrial biogenesis takes the level of oxidized 
products to one half (non-oxidized phospholipids and proteins are 
incorporated in mitochondrial biogenesis) (Figure 2).”
It is expected that slowing down the processes of brain mitochon-
drial dysfunction that occurs upon aging will provide a decrease of 
the neurological deficits in aged humans. Antioxidants targeted to 
mitochondria are promising therapeutic agents for human neuro-
degenerative diseases, however a huge research has to be performed 
(Reddy, 2007).
A series of antioxidants that can be described as mitochondria-
targeted are considered as follows.
vitaMin e
Chronic supplementation with high doses of vitamin E extended 
median life span by 39%, improved neurological functions by 
25–28% in aging mice (Navarro et al., 2005a) and improved brain 
mitochondrial function in aging mice and rats. Vitamin E reduced 
the inhibition of brain complex I activity produced by aging from 
36% to 12–14% in mice (Navarro et al., 2005a) and the inhibition of 
the malate-glutamate supported state 3 respiration of hippocampal 
and frontal cortex mitochondria from 23–29% to 4–10% (Table 2). 
Dietary supplementation with vitamin E increased α-tocopherol 
levels in mouse brain from 11.5 to 26.2 nmol/g brain (Navarro 
et al., 2005a). It is then clear that vitamin E (431 Da) crosses the 
blood-brain barrier, a process reserved to relatively small molecules 
(<450 Da) with lipophylic character, given to vitamin E by the chro-
man ring and the isoprenoid chain, and with less than 10 hydrogen 
bonds (Fand and McNally, 1981; Vatassery et al., 2004). The effect 
of vitamin E on the prevention of the aging-dependent decline 
in mitochondrial function was dose-dependent: 2.0 and 5.0 g of 
The mitochondrial adaptive response of mtNOS in neurodegen-
erative diseases is speculated as an increased mtNOS activity that 
supports an increased mitochondrial biogenesis in order to provide 
an increased energy supply. A 48% increase in the mitochondrial 
mass of human brain cortex was reported in Parkinson’s disease 
patients (Navarro et al., 2009) and the observation was interpreted 
as an adaptive response for the respiratory impairment with a pre-
sumable shortage in ATP supply. The decrease in maximal (state 3) 
respiratory activity is estimated in the range of 34–59%, seeming 
that the adaptive response in mitochondrial mass provides the same 
energy production than in the state of health.
The current views on Parkinson’s disease consider that this dis-
ease is not only characterized by substantia nigra dysfunction but 
that also involves the frontal cortex with a cognitive decline at the 
early stages of parkinsonism (McNamara et al., 2007). Oxidative and 
nitrosative damage and mitochondrial dysfunction in the human 
frontal cortex are to be considered factors leading to impaired cog-
nition in Parkinson’s disease.
It is currently considered that the energy demands of brain and 
central nervous system are provided by very active glucose oxida-
tion and aerobic metabolism; it is accepted than the O
2 
uptake 
of brain and central nervous system accounts for about 20% of 
the O
2
 uptake in basal metabolic conditions. It has been recently 
postulated that brain phospholipid oxidation products, as TBARS 
and organic hydroperoxides, reach systemic circulation and that 
the final product malonaldehyde (measured as TBARS) is increased 
by 21% in the plasma of patients with Parkinson’s and Alzheimer’s 
diseases and with vascular dementia (Serra et al., 2009). An esti-
mation of the rate of brain lipid peroxidation in the mentioned 
neurodegenerative diseases indicates an about twice increased rate 
as compared to the normal condition.
Mitochondria targeted antioxidant therapy
The experimental recognition of the association between dys-
functional mitochondria, inhibition of electron transfer, and 
accumulation of oxidation products is interpreted as the result of 
the continuous production of the free radicals O2
-  and NO by the 
enzymes of the inner mitochondrial membrane. Determinations 
of the mitochondrial rates of O2
-  and of NO production indicate 
that they account for 1 % (O2
- ) and 2 % (NO) of the rates of brain 
O
2
 uptake. The chain reactions initiated by O2
-  and NO establish 
a continuous free radical processes that entail lipid peroxidation 
and protein oxidation. In terms of causality it seems that the proc-
esses of oxidative damage to phospholipids, of enzyme inactivation, 
Table 1 | Oxygen uptake and complex I and mtNOS activities of human brain cortex in healthy controls and in patients with Parkinson’s disease or 
with dementia with Lewy bodies.
Condition Oxygen uptake Complex I activity mtNOS activity 
 (ng-at O/min × g brain) (nmol cyt c/min × mg protein) (nmol NO/min × mg protein)
Healthy controls (n = 9) 386 ± 31 396 ± 24 4.0 ± 0.4
Parkinson’s disease (n = 7) 323 ± 16* 162 ± 14** 7.0 ± 0.5**
Dementia with Lewy’s bodies (n = 7) 312 ± 14** 226 ± 18** 6.8 ± 0.6**
Respiratory rates were determined in 1 mm3 human brain cortex cubes in air-saturated Krebs suspending medium at 30°C. The electron transfer activity of complex 
I was assayed as NADH-cytochrome c reductase and expressed in nmol cytochrome c reduced/min × mg protein. *p < 0.05; **p < 0.005. Modified from Navarro 
et al. (2009).
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other antioxidants
Other antioxidants, such as acetylcarnitine and lipoic acid (Hagen 
et al., 1998; Liu et al., 2002) and flavonoid-rich vegetable extracts 
(Sastre et al., 1998; Bickford et al., 1999), chronically administered 
to mice and rats also prevented the age-associated decline in neu-
rological functions and oxidative damage in brain mitochondria. 
In the case of the flavonoid rich extract Egb 761 given orally to rats, 
its administration was effective in preventing the appearance of 
enlarged mitochondria, of increased levels of 8-HO-d- guanosine 
and hydroperoxides, and of a decrease in membrane potential (Sastre 
et al., 1998). Similarly, rats treated chronically with acetylcarnitine 
showed a lower age-dependent decline in the mitochondrial oxida-
tion rate of NAD-dependent substrates (Cocco et al., 2005) and in 
the mitochondrial gene expression of complexes I, IV, and V and of 
adenine nucleotide translocase (Nicoletti et al., 2005).
α-tocopherol acetate/kg food produced a prevention of 22% and 
34% of the decline of respiration in rat hippocampal mitochon-
dria (Table 2). These two α-tocopherol levels (2.0 and 5.0 g of 
α-tocopherol acetate/kg food) in the rat diet would correspond, 
on the basis of the ratio: mg α-tocopherol/kJ of basal metabolic 
rate, to 0.90 and 2.1 g vitamin E/day in humans.
The effect of high doses of vitamin E on mice survival is to be 
taken into account in the controversy on the use of vitamin E sup-
plementation in humans. The claim that vitamin E supplementa-
tion increases human mortality, based on meta-analysis (Bjelakovic 
et al., 2007) is challenged by the clinical evidence that vitamin E 
supplements are safe at high intakes (Hathcock et al., 2005) and by 
the reported effects of vitamins E and C in the reduction of preva-
lence and incidence of Alzheimer disease in an elderly population 
(Zandi et al., 2004).
FIgurE 2 | Scheme illustrating the hypothesis of the time course of the levels of mitochondrial oxidation and nitration products, associated with 
mitochondrial turnover for brain mitochondria as a function of time and age. AU, arbitrary units. Modified from Navarro and Boveris (2008).
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respiratory chain. MitoVitE was reported to reduce H
2
O
2
-induced 
caspase activity (Hughes et al., 2005) and to prevent cell death in 
fibroblasts from patients with Friedrich ataxia, an inherited nerv-
ous system disease associated with decreased frataxin and increased 
iron-catalyzed oxidative damage (Jauslin et al., 2003), to inhibit 
cytochrome c release and caspase-3 activation, to inhibit complex 
I inactivation and to restore mitochondrial membrane potential in 
bovine aortic epithelial cells after oxidative stress (Reddy, 2006).
MitoQ
10
 is a similar TPP+ derivative with ubiquinone-50 (Q
10
) 
that is similarly accumulated in mitochondria. Internalized MitoQ
10
 
is inmobilized by anchoring the isoprenoid chain into the lipid 
bilayer and becomes redox active: the oxidized form is readily 
reduced by complex II and is reduced by complex I. The ubiqui-
nol molecule inserted in the mitochondrial inner membrane acts 
as a free radical trap and antioxidant preventing oxidative damage 
(Reddy, 2006). The electrical charge and the consequent superficial 
position of the TPP+ moiety and the solubility of Q
10
 in non-polar 
solvents indicate the isoprenoid chain of MitoQ
10
 concentrates in 
the membrane core where it quenches fluorophors deep within the 
membrane. In isolated cells, MitoQ
10
 protects from H
2
O
2
-induced 
apoptosis but not from the apoptosis induced by staurosporine or 
TNF-α (Murphy and Smith, 2007).
MitoPBN is another TPP+ derivative, in this case with phenoxy-
butyl-nitrone, that was designed to prevent mitochondrial lipid 
peroxidation and oxidative damage based on the well known and 
relatively selective PBN reaction with carbon-centered radicals 
(R.) and peroxyl radicals (ROO.) (Murphy et al., 2003). MitoPBN 
is rapidly taken up by mitochondria reaching intramitochon-
drial levels of 2.2–4.0 mM. MitoPBN was observed to block the 
oxygen-induced activation of uncoupling proteins (Murphy et al., 
2003). An amphiphilic molecule derived from PBN and that is 
the skulachev cations attached to antioxidant Molecules
A new family of mitochondrial antioxidants is being developed. The 
new mitochondria-targeted antioxidants are covalent derivatives of 
vitamin E, ubiquinone, and PBN (α-phenyl-N-tert-butyl nitrone) 
that are covalently coupled to a triphenylphosphonium cationic 
group (Murphy and Smith, 2007). The phosphonium derivatives 
have been used for years in the determination of inner membrane 
potential and, following to the development and use by Russian 
bionergeticists, are commonly known as the “Skulachev cations.” 
Lipophilic triphenyl-phosphonium cations are actively taken up by 
mitochondria due to the inner membrane potential (160–170 mV) 
with the inside negative, that according to the electrochemical 
potential (Guggenheim equation) produces an intramitochon-
drial accumulation of about 700 times (Skulachev, 2005, 2007). 
The development and use of the phosphonium antioxidants takes 
advantage of the unique mitochondrial biophysical and biochemi-
cal characteristics that provide a negatively charged compartment 
and a reducing environment that allows regeneration of the free 
radical scavengers.
The molecule resulting from the coupling of triphenylphos-
phonium cation (TPP+) with α-tocopherol, is called MitoVitE 
and was developed to prevent mitochondrial oxidative damage. 
Mitochondria incubated with 1–20 μM MitoVitE take up the phos-
phonium cations in about 15–30 min with accumulation ratios 
of up to 1000 times (Sheu et al., 2006). Higher levels of MitoVitE 
(50 μM) in the incubation medium are cytotoxic for Jurkat cells 
(Sheu et al., 2006). It is considered that MitoVitE is inserted in the 
lipid bilayer of the mitochondrial inner membrane and that the 
chroman group becomes redox active. The semiquinone, formed 
after detoxifying a free radical by hydrogen donation, is reduced by 
electron transfer or tunneling from a reduced component of the 
Table 2 | Effect of high doses of dietary vitamin E in tissue and mitochondrial respiration in frontal cortex, hippocampus, and whole brain of 
aging rats.
Condition/tissue Brain oxygen uptake (ng-at O/min × g brain) Mitochondrial respiration State 3 
   and malate-glutamate as substrate 
   (ng-at O/min × mg protein)
CONTrOL rATS (4 MONThS)
Frontal cortex 1004 ± 21 (100%) 132 ± 7 (100%)
Hippocampus 1003 ± 22 (100%) 103 ± 7 (100%)
Whole braina 992 ± 21 (100%) 135 ± 8 (100 %)
CONTrOL rATS (12 MONThS)
Frontal cortex 772 ± 18* (77%) 94 ± 8* (71%)
Hippocampus 709 ± 18* (71%) 65 ± 6* (73%)
Whole braina 770 ± 18* (78%) 109 ± 7* (81%)
rATS (12 MONThS) rECEIVINg VITAMIN E: 2.0 g/α-TOCOPhErOL ACETATE/Kg FOOd FOr 3 MONThS
Frontal cortex 906 ± 19† (90%) 119 ± 7† (90%)
Hippocampus 912 ± 20† (91%) 94 ± 7† (92%)
Whole braina 850 ± 19† (86%) 118 ± 8 (88%)
rATS (12 MONThS) rECEIVINg VITAMIN E: 5.0 g/α-TOCOPhErOL ACETATE/Kg FOOd FOr 3 MONThS
Frontal cortex 944 ± 21† (94%) 125 ± 9† (95%)
Hippocampus 963 ± 21† (96%) 100 ± 8† (96%)
Whole braina 932 ± 21† (94%) 124 ± 9† (92%)
aBrain tissue cubes were from striatum and occipital and parietal areas. *p < 0.05, 12 months rats compared with 4 months rats; †p < 0.05, rats supplemented with 
vitamin E compared with non-supplemented animals (all at 12 months of rat age). Unpublished data from Navarro’s laboratory.
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A. This  mechanism is supported by observations in brain, kidney, 
liver, heart, and muscle (Nisoli et al., 2004) and ovary (Navarro 
et al., 2005b). However, it has to kept in mind that NO effects 
are expected to be finely tuned up according to NO levels and to 
the cell redox environment and that in such scenario, both neuro-
trophic and neurotoxic effects of NO are likely. Moderate exercise 
has been recognized effective in increasing brain mtNOS activity; 
mice subjected to moderate exercise during 12 days increases 2.5 
times mtNOS activity in mouse brain (Boveris and Navarro, 2008b). 
The effect was explained as the activation of a muscle-initiated 
neural pathway that activates mtNOS synthesis in the brain (as it 
occurs in endorphin synthesis). Pyrroloquinone has been found 
to increase mitochondrial biosynthesis in cell cultures and opens a 
perspective for diseases associated with mitochondrial dysfunction 
(Chowanadisai et al., 2010).
concluding reMarks
The long standing concept of linking aging and an impaired mito-
chondrial energy supply is now receiving experimental support. It 
has been recognized that aging is associated with a decreased mito-
chondrial function, considered primarily as electron transfer and 
respiration, in a series of organs as brain, heart, liver, and kidney. 
Brain mitochondria are more affected by the aging process than 
the mitochondria of other organs. This observation agrees with 
the general concept that the physiological functions that depend 
on the integrated response of the central nervous system are the 
most affected by aging.
The complex series of factors contributing to brain senescence 
and neurodegeneration in experimental animals, mice and rats, 
and humans converge to show a condition of brain mitochondrial 
dysfunction with two simultaneous conditions: impaired electron 
transfer and enzymatic activity and mitochondrial oxidative dam-
age. Brain dysfunctional mitochondria accumulate in aged rodents 
and show marked decreases in the rates of active (+ADP) res-
piration, especially with malate–glutamate as substrate, marked 
decreases in the rates of electron transfer in complexes I and IV, 
decreased membrane potential, increased content of the oxidation 
products of phospholipids and proteins, and increased size and 
fragility. In humans, data is starting to accumulate and shows about 
the same general picture dominated by complex I inactivation, 
with the corresponding impairment of mitochondrial respiration 
in the presence of NAD-linked substrates and the always present 
increased content of the oxidation products of phospholipids and 
proteins. Interestingly, complex I and IV activities are consistently 
reported decreased in aged rats and mice. However in human 
neurodegenerative diseases the observations are consistent with 
complex I inactivation but not with complex IV inactivation. Both 
complexes are large molecules that are composed by a series of 
polypeptides and that are embedded in the phospholipid bilayer of 
the mitochondrial inner membrane. In both cases, phospholipids 
are necessary for enzyme activity; this can be easily understood 
as due to the hydrophobic bonding that holds together enzyme 
polypeptides and membrane phospholipids. Subtle differences 
in biological species phospholipid composition may account for 
the difference in complex IV sensitivity to aging in rats and mice 
and the complex IV insensitivity to neurodegenerative diseases 
in humans.
a  nitronium cation (LPBNAH) shows a neuroprotective activity 
antagonizing oxidative damage of mitochondrial origin (Poeggeler 
et al., 2005).
Currently, other antioxidants of the phosphonium type are 
developed as effective mitochondria-targeted antioxidants (Kelso 
et al., 2001; James et al., 2007). For instance, the derivative with 
the selenium-containing ebselen shows hydroperoxide peroxidase 
activity (Mugesh et al., 2001).
tetrapeptide antioxidants
The series of the “SS tetrapeptides” is constituted by aromatic-
 cationic peptides that have the structural motif of alternating aro-
matic and basic amino acids with 2, 6-dimethyltyrosine residues 
(Sheu et al., 2006). These tetrapeptides, that were originally pre-
pared to act as opioid analgesics, are taken up by isolated cells and 
mitochondria due to their positive charge at physiological pH and 
show the antioxidant properties of dimethyltyrosine, a classic phe-
nolic antioxidant (Zhao et al., 2003a,b). Four main SS tetrapeptides 
have been developed: SS-02, SS-19, SS-20, and SS-31 (Sheu et al., 
2006). Peptides SS-02 and SS-19 are actively taken up by mouse 
liver mitochondria and human CaCo-2 cells, with an intracellular 
localization in mitochondria and with a 100-fold accumulation in 
mitochondria. The mitochondrial uptake of SS-19 was decreased by 
the uncoupler FCCP, indicating a potential-dependent accumula-
tion (Zhao et al., 2004).
Three structure–property relationships illustrate how this anti-
oxidants work: SS-20 that lacks the dimethyltyrosine of SS-02 also 
lacks antioxidant properties; SS-31 contains the same amino acids 
that SS-02, but in a sequence with better antioxidant properties; 
and SS-19 is more lipophylic and fluorescent due to the anthranyl 
group. Concerning antioxidant properties, SS-02 showed anti-
oxidant properties in a cell-free system and inhibited the H
2
O
2
-
promoted oxidation of linoleic acid and of low-density lipoproteins 
(Zhao et al., 2003b) and SS-31 protected against oxidant-induced 
mitochondrial dysfunction and apoptosis in isolated neurons of 
the N2a and SH-SY5Y cell lines (Zhao et al., 2004). Treatment 
of the neurons with t-butyl-hydroperoxide resulted in increased 
lipid peroxidation, phosphatidylserine translocation, mitochon-
drial depolarization, increased caspase activity, nuclear condensa-
tion, and cell death by apoptosis and SS-31 was able to partially 
prevent the oxidative damage produced by t-butyl-hydroperoxide. 
The remarkable potency of SS-31 (effects are reported at 1 nM) is 
explained by extensive cellular and mitochondrial accumulation 
(about 5000-fold in the mitochondrial pellet (Zhao et al., 2005). 
It was reported that SS-19 decreases mitochondrial O2
-  production 
and cellular lipid peroxidation and improves the contractile force 
and myocardial stunning in perfused hearts subjected to ischemia-
reperfusion (Zhao et al., 2005).
Mitochondrial biogenesis, cellular no, and Mitochondrial 
no production
Nitric oxide signaling for mitochondrial biogenesis and turnover 
is a recent concept in cell biology. The NO-dependent pathway of 
mitochondrial biogenesis includes activation of guanylate cyclase, 
increased levels of cGMP, and activation of a series of transcrip-
tion factors, such as PPAR-GC-1α, nuclear respiratory factors 
(NRF-1 and NRF-2) and mitochondrial transcription factor 
Frontiers in Aging Neuroscience www.frontiersin.org September 2010 | Volume 2 | Article 34 | 9
Navarro and Boveris Mitochondrial dysfunction in brain
ing oral administration. Arch. Int. 
Pharmacodyn. Ther. 250, 4–17.
Gatto, E. M., Riobo, N. A., Carreras, M. 
C., Chernavsky, A., Rubio, A., Satz, 
M. L., and Poderoso, J. J. (2000). 
Overexpression of neutrophil neuro-
nal nitric oxide synthase in Parkinson’s 
disease. Nitric Oxide 4, 534–539.
Gerschman, R., Gilbert, D. L., Nye, S. W., 
Dwyer, P., and Fenn, W. O. (1954). 
Oxygen poisoning and x-irradiation: 
a mechanism in common. Science 119, 
623–626.
Ghafourifar, P., and Richter, C. (1997). 
Nitric oxide synthase activity in mito-
chondria. FEBS Lett. 418, 291–296.
Gilad, G. M., and Gilad, V. H. (1995). 
Strain, stress, neurodegeneration 
and longevity. Mech. Ageing Dev. 78, 
75–83.
Giulivi, C., Poderoso, J. J., and Boveris, 
A. (1998). Production of nitric oxide 
by mitochondria. J. Biol. Chem. 273, 
11038–11043.
Gomez, C., Bandez, M. J., and Navarro, 
A. (2007). Pesticides and impairment 
of mitochondrial function in relation 
with the parkinsonian syndrome. 
Front. Biosci. 12, 1079–1093.
Gonzalez-Flecha, B., Cutrin, J. C., and 
Boveris, A. (1993). Time course and 
mechanism of oxidative stress and 
tissue damage in rat liver subjected to 
in vivo ischemia-reperfusion. J. Clin. 
Invest. 91, 456–464.
Good, P. F., Hsu, A., Werner, P., Perl, 
D. P., and Olanow, C. W. (1998). 
Protein nitration in Parkinson’s dis-
ease. J. Neuropathol. Exp. Neurol. 57, 
338–342.
Hagen, T. M., Ingersoll, R. T., Wehr, 
C. M., Lykkesfeldt, J., Vinarsky, V., 
G. A., and Rucker, R. B. (2010). 
Pyrroloquinoline quinone stimulates 
mitochondrial biogenesis through 
cAMP response element-binding pro-
tein phosphorylation and increased 
PGC-1alpha expression. J. Biol. Chem. 
285, 142–152.
Cocco, T., Sgobbo, P., Clemente, M., 
Lopriore, B., Grattagliano, I., Di, P. 
M., and Villani, G. (2005). Tissue-
specific changes of mitochondrial 
functions in aged rats: effect of a 
long-term dietary treatment with 
N-acetylcysteine. Free Radic. Biol. 
Med. 38, 796–805.
Cutler, R. G. (1991). Antioxidants 
and aging. Am. J. Clin. Nutr. 53: 
373S–379S.
Dawson, T. M., and Dawson, V. L. (2003). 
Molecular pathways of neurodegen-
eration in Parkinson’s disease. Science 
302, 819–822.
Dennis, J., and Bennett, J. P. Jr. (2003). 
Interactions among nitric oxide and 
Bcl-family proteins after MPP+ expo-
sure of SH-SY5Y neural cells I: MPP+ 
increases mitochondrial NO and Bax 
protein. J. Neurosci. Res. 72, 76–88.
Elfering, S. L., Sarkela, T. M., and Giulivi, 
C. (2002). Biochemistry of mitochon-
drial nitric-oxide synthase. J. Biol. 
Chem. 277, 38079–38086.
Eve, D. J., Nisbet, A. P., Kingsbury, A. E., 
Hewson, E. L., Daniel, S. E., Lees, A. 
J., Marsden, C. D., and Foster, O. J. 
(1998). Basal ganglia neuronal nitric 
oxide synthase mRNA expression in 
Parkinson’s disease. Brain Res. Mol. 
Brain Res. 63, 62–71.
Fand, I., and McNally, W. P. (1981). 
Whole-body localization of 14C-
tocopheryl acetate in the rat follow-
Boveris, A., and Stoppani, A. O. (1971). 
Inhibition of mitochondrial swelling 
by 19-nor-ethynyltestosterone acetate 
and other steroids. Arch. Biochem. 
Biophys. 142, 150–156.
Boveris, A., Valdez, L. B., Zaobornyj, T., and 
Bustamante, J. (2006). Mitochondrial 
metabolic states regulate nitric oxide 
and hydrogen peroxide diffusion to 
the cytosol. Biochim. Biophys. Acta 
1757, 535–542.
Brown, G. C., and Borutaite, V. (2004). 
Inhibition of mitochondrial respira-
tory complex I by nitric oxide, perox-
ynitrite and S-nitrosothiols. Biochim. 
Biophys. Acta 1658, 44–49.
Carreras, M. C., Franco, M. C., Peralta, J. 
G., and Poderoso, J. J. (2004). Nitric 
oxide, complex I, and the modulation 
of mitochondrial reactive species in 
biology and disease. Mol. Aspects Med. 
25, 125–139.
Cassarino, D. S., Halvorsen, E. M., 
Swerdlow, R. H., Abramova, N. N., 
Parker, W. D. Jr., Sturgill, T. W., and 
Bennett, J. P. Jr. (2000). Interaction 
among mitochondria, mitogen-ac-
tivated protein kinases, and nuclear 
factor-kappaB in cellular models of 
Parkinson’s disease. J. Neurochem. 74, 
1384–1392.
Chagnon, P., Betard, C., Robitaille, Y., 
Cholette, A., and Gauvreau, D. (1995). 
Distribution of brain cytochrome oxi-
dase activity in various neurodegenera-
tive diseases. Neuroreport 6, 711–715.
Chance, B., Sies, H., and Boveris, A. 
(1979). Hydroperoxide metabolism 
in mammalian organs. Physiol. Rev. 
59, 527–605.
Chowanadisai, W., Bauerly, K. A., 
Tchaparian, E., Wong, A., Cortopassi, 
references
Beckman, K. B., and Ames, B. N. (1998). 
The free radical theory of aging 
matures. Physiol. Rev. 78, 547–581.
Bickford, P. C., Shukitt-Hale, B., and 
Joseph, J. (1999). Effects of aging 
on cerebellar noradrenergic func-
tion and motor learning: nutritional 
interventions. Mech. Ageing Dev. 111, 
141–154.
Bjelakovic, G., Nikolova, D., Gluud, L. L., 
Simonetti, R. G., and Gluud, C. (2007). 
Mortality in randomized trials of 
antioxidant supplements for primary 
and secondary prevention: systematic 
review and meta-analysis. JAMA 297, 
842–857.
Bougria, M., Vitorica, J., Cano, J., and 
Machado, A. (1995). Implication 
of dopamine transporter system 
on 1-methyl-4-phenylpyridinium 
and rotenone effect in striatal syn-
aptosomes. Eur. J. Pharmacol. 291, 
407–415.
Boveris, A., and Cadenas, E. (2000). 
Mitochondrial production of hydro-
gen peroxide regulation by nitric 
oxide and the role of ubisemiquinone. 
IUBMB Life 50, 245–250.
Boveris, A., and Chance, B. (1973). The 
mitochondrial generation of hydrogen 
peroxide. General properties and effect 
of hyperbaric oxygen. Biochem. J. 134, 
707–716.
Boveris, A., and Navarro, A. (2008a). Brain 
mitochondrial dysfunction in aging. 
IUBMB Life 60, 308–314.
Boveris, A., and Navarro, A. (2008b). 
Systemic and mitochondrial adap-
tive responses to moderate exercise 
in rodents. Free Radic. Biol. Med. 44, 
224–229.
as the Skulachev cations (derivatives of the phosphonium cation 
that covalently attached to either vitamin E, or ubiquinone or PBN) 
and the SS tetrapeptides, are under development and testing. These 
molecules are negatively charged and accumulate in mitochondria 
where they exert their antioxidant effects.
Activation of the cellular mechanisms that regulate mitochon-
drial biogenesis is another potential therapeutic strategy, consider-
ing that de novo generated mitochondria are devoid of oxidation 
products and show full enzymatic activity and full capacity for 
ATP production. Then, stimulation of mitochondrial biogenesis 
is a novel approach with a potential of beneficial effects in neu-
rodegenerative diseases that are associated with mitochondrial 
dysfunction.
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The oxidative mitochondrial partial inactivation of complex 
I accompanied by oxidative damage is a phenomenon, in short 
named “complex I syndrome,” that is being recognized as charac-
teristic of mammalian brain aging and of human neurodegenera-
tive diseases. Mitochondrial dysfunction has been recognized as 
a more marked phenomenon, in terms of complex I syndrome, 
in brain areas as hippocampus and frontal cortex in rats, human 
cortex in Parkinson’s disease and dementia with Lewy bodies, and 
substantia nigra in Parkinson disease. The molecular mechanism 
involved in complex I inactivation is likely accounted by the syn-
ergistic effects of ONOO−, by reactions with the free radical inter-
mediates of the lipid peroxidation process, and by amine–aldehyde 
adduction reactions.
The accumulation of mitochondrial oxidation products in rodent 
aging and in neurodegenerative diseases prompted the idea of anti-
oxidant therapies. High doses of vitamin E showed a highly signifi-
cant protection of complex I activity and mitochondrial function, 
with improvement of neurological functions and with an increased 
median life span in mice. Other antioxidants showed similar effects. 
Interestingly a whole family of mitochondria-targeted antioxidants, 
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